Status: Not yet recruiting
Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia
The goal of this clinical trial is to evaluate the efficacy of gilteritinib as induction therapy in FLT3-positive adult acute myeloid leukemia patients. The main question it aims to answer is: Is gilteritinib in combination to chemotherapy able to improve the complete remission rate of FLT3-positive AML? Participants will receive up to 2 induction cycles with gilteritinib in combination with FLAI (fludarabine, cytarabine, idarubicine) and up to 3 consolidation cycles with gilteritinib and high-dose cytarabine.
Participants needed: 80
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Gruppo Italiano Malattie EMatologiche dell'AdultoUpdated: Mar 12, 2025
Eligibility criteria
The patient is ≥ 18 and ≤65 years old. [+12]
Patient was diagnosed as acute promyelocytic leukemia. [+11]